Kemudin I.V.

Active Ingredient:: Ceftriaxone
Origin:: EU

Kemudin I.V. (Ceftriaxone)

Q: What is Kemudin I.V. used for?

Kemudin I.V. contains ceftriaxone, a broad‑spectrum third‑generation cephalosporin used to treat serious bacterial infections such as community‑acquired pneumonia, bacterial meningitis, gonorrhea, complicated urinary tract infections, and skin‑soft‑tissue infections. It is administered intravenously in hospital settings under the direction of a qualified prescriber.

Q: How does ceftriaxone work?

Ceftriaxone works by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan cross‑linking. This inhibition weakens the cell wall, causing osmotic lysis and death of susceptible Gram‑negative and Gram‑positive bacteria.

Q: What is the usual dose of Kemudin I.V.?

The dosing regimen for Kemudin I.V. is individualized by the treating physician based on the infection type, severity, patient age, weight, and renal or hepatic function. Clinicians determine the appropriate dose, frequency, and duration according to current clinical guidelines.

Q: Is Kemudin I.V. safe in pregnancy or breastfeeding?

The safety of ceftriaxone during pregnancy and lactation has not been definitively established; it is classified as pregnancy category unknown. Prescribers must weigh the potential benefits against possible risks and consider alternative therapies when appropriate.

Q: How do I order Kemudin I.V. from GNH India?

To order Kemudin I.V., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Q: How does Kemudin I.V. compare with other antibiotics?

Compared with earlier‑generation cephalosporins, ceftriaxone offers a broader spectrum against Gram‑negative organisms and a longer half‑life, allowing once‑daily dosing. It is often preferred over cefotaxime for its convenient dosing schedule, though both share similar safety profiles. Resistance patterns and infection site guide the choice of alternative agents.

Q: How should Kemudin I.V. be stored and handled?

Kemudin I.V. must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Before administration, inspect for particulate matter and ensure the solution is clear.

Q: How is Kemudin I.V. administered?

Kemudin I.V. is given by intravenous injection or infusion. The preparation is diluted in compatible IV fluids and administered over 30 minutes to 2 hours, depending on the dose and clinical situation. Administration should be performed by trained healthcare personnel following aseptic technique.

Q: What are the most serious risks associated with Kemudin I.V.?

Serious adverse events include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, hemolytic anemia, and significant hepatic dysfunction. Prompt recognition and discontinuation of the drug are essential if any of these reactions occur.

Q: Who should not use Kemudin I.V.?

Kemudin I.V. is contraindicated in patients with a known hypersensitivity to ceftriaxone, other cephalosporins, or any β‑lactam antibiotics. Caution is also advised for neonates under 28 days receiving calcium‑containing solutions due to the risk of precipitation.

Ceftriaxone, the active ingredient in Kemudin I.V., is a third‑generation cephalosporin presented as an injection solution for intravenous use. It treats a broad range of serious bacterial infections, including pneumonia, meningitis, gonorrhea, urinary tract infections, and skin‑soft‑tissue infections in adults and children.

GNH India supplies Kemudin I.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides regulated, quality‑assured products to healthcare facilities across multiple continents.

Manufacturer / TM Owner

Laboratórios Basi – Indústria Farmacêutica, S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ceftriaxone is a broad‑spectrum antibacterial that targets Gram‑negative and Gram‑positive organisms in several infection categories.

Community‑acquired pneumonia: effective bacterial eradication leading to clinical recovery.
Bacterial meningitis: rapid bactericidal activity reduces mortality and neurological complications.
Gonorrhea: single‑dose therapy eliminates Neisseria gonorrhoeae infection.
Urinary tract infections: resolves complicated UTIs caused by susceptible organisms.
Skin and soft‑tissue infections: clears cellulitis and wound infections caused by susceptible bacteria.

How It Works

Ceftriaxone exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis. Its high affinity for a broad range of PBPs provides activity against many Gram‑negative and some Gram‑positive pathogens, including resistant strains.

Side Effects

Ceftriaxone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

Injection site pain: mild discomfort at the infusion site.
Diarrhea: loose stools, often self‑limited.
Nausea: occasional feeling of queasiness.
Rash: mild skin erythema.
Elevated liver enzymes: transient increase in ALT/AST.
Headache: mild to moderate.

Serious or Rare Side Effects

Anaphylaxis: severe allergic reaction with respiratory distress.
Stevens‑Johnson syndrome: rare severe skin and mucosal detachment.
Clostridioides difficile‑associated diarrhea: severe colitis.
Hemolytic anemia: immune‑mediated red cell destruction.
Severe hepatic dysfunction: jaundice, elevated bilirubin.
Pseudomembranous colitis: inflammation of colon.

Precautions & Warnings

Before using Ceftriaxone, clinicians should consider several safety precautions to minimize risk.

Renal impairment: adjust dosing and monitor renal function.
Hepatic impairment: use with caution; monitor liver enzymes.
Neonates and infants <28 days: risk of bilirubin displacement; avoid high doses.
Known allergy to β‑lactams: contraindicated due to risk of severe hypersensitivity.
Pregnancy and lactation: safety category unknown; weigh benefits against potential risks.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ceftriaxone interacts with several drugs, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

Calcium‑containing IV solutions: precipitation can occur; avoid simultaneous administration.
Warfarin: enhanced anticoagulant effect may increase bleeding risk.
Aminoglycosides: combined nephrotoxicity; monitor renal function closely.

Moderate Interactions (Monitor Closely)

NSAIDs: may increase risk of renal impairment.
Oral contraceptives: possible reduction in contraceptive effectiveness.
Diuretics: may affect electrolyte balance and renal clearance.
Probenecid: can increase ceftriaxone plasma levels, adjust dose if needed.

Frequently Asked Questions

Kemudin I.V. contains ceftriaxone, a broad‑spectrum third‑generation cephalosporin used to treat serious bacterial infections such as community‑acquired pneumonia, bacterial meningitis, gonorrhea, complicated urinary tract infections, and skin‑soft‑tissue infections. It is administered intravenously in hospital settings under the direction of a qualified prescriber.

Ceftriaxone works by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan cross‑linking. This inhibition weakens the cell wall, causing osmotic lysis and death of susceptible Gram‑negative and Gram‑positive bacteria.

The dosing regimen for Kemudin I.V. is individualized by the treating physician based on the infection type, severity, patient age, weight, and renal or hepatic function. Clinicians determine the appropriate dose, frequency, and duration according to current clinical guidelines.

The safety of ceftriaxone during pregnancy and lactation has not been definitively established; it is classified as pregnancy category unknown. Prescribers must weigh the potential benefits against possible risks and consider alternative therapies when appropriate.

To order Kemudin I.V., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Compared with earlier‑generation cephalosporins, ceftriaxone offers a broader spectrum against Gram‑negative organisms and a longer half‑life, allowing once‑daily dosing. It is often preferred over cefotaxime for its convenient dosing schedule, though both share similar safety profiles. Resistance patterns and infection site guide the choice of alternative agents.

Kemudin I.V. must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Before administration, inspect for particulate matter and ensure the solution is clear.

Kemudin I.V. is given by intravenous injection or infusion. The preparation is diluted in compatible IV fluids and administered over 30 minutes to 2 hours, depending on the dose and clinical situation. Administration should be performed by trained healthcare personnel following aseptic technique.

Serious adverse events include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, hemolytic anemia, and significant hepatic dysfunction. Prompt recognition and discontinuation of the drug are essential if any of these reactions occur.

Kemudin I.V. is contraindicated in patients with a known hypersensitivity to ceftriaxone, other cephalosporins, or any β‑lactam antibiotics. Caution is also advised for neonates under 28 days receiving calcium‑containing solutions due to the risk of precipitation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.